Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this 
announcement. 
----------------------------------------------------------------------
--------------    




Consolidated revenue increases by 7.2 percent to EUR 478.5 million -
cash flow from operating activities doubles in the reporting period
(JENA, 13 August 2009) Despite persistently difficult economic
conditions, Carl Zeiss Meditec AG held its own again in the first
nine months of 2008/2009 (1 October 2008 - 30 June 2009). Thanks to
its broad portfolio and global orientation, the company generated
solid growth of 7.2 percent to EUR 478.5 million. Carl Zeiss Meditec
increased earnings before interest and taxes disproportionately to
revenue, by 11.0 percent to EUR 53.6 million (previous year: EUR 48.3
million).
"These results prove that our operations have taken the right path.
Thanks to solid consolidated net income, to which all business units
contributed, and strong receivables management, we managed to double
the operating cash flow in the first nine months to EUR 58.6 million.
This financial stability lends us competitive strength", explains Dr.
Michael Kaschke, President and CEO of Carl Zeiss Meditec AG.
Due to a lower financial result following a fall in the interest
rates on capital investments, the consolidated net income after
minority interests from October 2008 to June 2009, at EUR 32.5
million, was lower than the prior-year value (EUR 36.4 million).
Earnings per share after minority interests totalled EUR 0.40
(previous year: EUR 0.45) in the first nine months of 2008/2009.

Growth course in all business units
The "Ophthalmic Systems" strategic business unit, which primarily
deals in diagnostic and treatment systems for ophthalmology, recorded
a satisfactory revenue increase of 13.2 percent during the reporting
period to EUR 232.2 (previous year: EUR 205.1) million. Here the
company benefitted, in particular, from its innovative products and
the currency development of the US dollar and the yen against the
euro.
In the area of implants and consumables for ophthalmology, the
"Surgical Ophthalmology" strategic business unit, revenue grew by 5.3
percent to EUR 61.6 (previous year: EUR 58.4) million, which was
primarily due to higher revenues with innovative intraocular lenses.
Due to the reluctance in some cases to invest in the hospital sector,
revenue in the Microsurgery SBU only increased slightly in the first
nine months to EUR 184.7 (previous year: EUR 183.0) million. This
growth was driven by the innovative surgical microscopes OPMI®
Pentero® for neurosurgery and OPMI Lumera® for ophthalmic surgery.
The "Microsurgery" SBU accounted for a 38.6 percent share of revenue
(previous year: 41.0 percent), while the "Ophthalmic Systems" SBU
contributed 48.5 percent (previous year: 45.9 percent) and the
"Surgical Ophthalmology" SBU the remaining 12.9 percent (previous
year: 13.1 percent).


Asia/Pacific shows high growth rates
Carl Zeiss Meditec continued to generate high growth rates in the
"Asia/Pacific" region during the first nine months of 2008/2009.
Revenue in this region rose by 20.2 percent year-on-year to EUR 128.2
million (previous year: EUR 106.7 million). In addition to the
Japanese market, the Indian market also contributed to this
development. The region's share of revenue increased slightly to 26.8
percent, compared with 23.9 percent in the previous year.
The "Americas" region was once again the strongest generator of sales
in the first nine months of 2008/2009. Here revenue increased by 9.6
percent from EUR 151.2 million to EUR 165.7 million. Positive
influences came from sales of innovative diagnostic equipment and
surgical microscopes. In addition, the same period of the previous
year was significantly influenced by economic turbulence, especially
in the United States. The region's share of revenue increased
slightly to 34.7 percent, compared with 33.8 percent in the previous
year. The proportion of Carl Zeiss Meditec's revenue generated by
Germany as a regional market decreased compared with the same period
of the previous year from 8.9 percent to 8.3 percent.
The sales drivers in the "Europe, Middle East and Africa" (EMEA)
region were diagnostic systems, surgical microscopes and intraocular
lenses. Revenue amounted to EUR 144.8 million (previous year: EUR
149.0 million) in the reporting period. The proportion of
consolidated revenue generated by this region decreased from 33.4
percent to 30.2 percent year-on-year

Positive outlook for financial year 2008/2009
Given a strong order intake at the end of Q3 of this financial year,
Carl Zeiss Meditec expects at least five percent revenue growth with
stable profitability for financial year 2008/2009.
President and CEO Dr. Kaschke explains: "However, it is the medium-
and long-term outlook that is more important to us than short-term
developments: for our objective is to achieve sustainable profitable
growth. In the longer-term we are well-equipped, thanks to our
strategic orientation, our technological innovative strength and our
financial muscle, to continue our investment even now into
customer-oriented innovations and into strengthening our sales and
service structures. This puts us in a position to successfully
overcome the challenges that arise in the near future."

Press contacts:
Eva Sesselmann
Corporate Communications
Carl Zeiss Meditec AG
Göschwitzer Straße 51-52
07745 Jena
Phone: +49 3641 220-331
Phone: +49 3641 220-112
E-mail: press@meditec.zeiss.com
 Patrick Kofler
Investor Relations
Carl Zeiss Meditec AG
Göschwitzer Straße 51-52
07745 Jena
Phone: +49 3641 220-106
Phone: +49 3641 220-117
E-mail: investors@meditec.zeiss.com

Brief profile
Carl Zeiss Meditec AG (ISIN: DE 0005313704) is listed in the Tec-DAX
of the Deutsche Börse and is one of the world's leading medical
technology suppliers.
The company supplies innovative technologies and application-oriented
solutions designed to help doctors improve the quality of life of
their patients. The Company offers complete solutions, including
implants and consumables, to diagnose and treat ophthalmic diseases.
The company creates innovative visualisation solutions in the field
of microsurgery. Carl Zeiss Meditec's medical technology portfolio is
rounded off by promising future technologies, such as intraoperative
radiation therapy.
In the 2007/2008 (30 September) financial year the 2,100 employees
generated revenue of approximately 600 EUR million. The registered
office of Carl Zeiss Meditec is located in Jena, Germany. The company
has subsidiaries in Germany and abroad; more than 50 percent of its
employees are based in the USA, Japan, Spain and France.
35 percent of Carl Zeiss Meditec shares are in free float. The
remaining 65 percent are held by Carl Zeiss AG, one of the world's
leading groups engaged in the optical and opto-electronics industry.
The five independently run business segments of Carl Zeiss AG operate
in the future markets "Medical and Research Solutions", "Industrial
Solutions" and "Lifestyle Products". The head office of Carl Zeiss AG
is in Oberkochen, Germany. In financial year 2007/08 (balance sheet
date 30 September) the group posted sales of around EUR 2.7 billion.
Carl Zeiss has a total workforce of about 13,000 in over 30
countries, over 8,000 of them in Germany.
Further information: http://www.meditec.zeiss.de


 
--- End of Message ---

Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany

WKN: 
531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share, 
TecDAX;
Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse 
Stuttgart, 
Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, 
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr 
in Niedersächsische Börse zu Hannover, 
Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in 
Frankfurter Wertpapierbörse;



Copyright © Hugin AS 2009. All rights reserved.